BRPI0909270A2 - Sirna Compounds for Inhibition of rtp801 - Google Patents

Sirna Compounds for Inhibition of rtp801

Info

Publication number: BRPI0909270A2
Authority: BR; Brazil
Prior art keywords: rtp801; inhibition; sirna compounds; sirna; compounds
Prior art date: 2008-03-20

Application number

BRPI0909270-6A

Other languages

Portuguese (pt)

Inventor

Elena Feinstein

Rami Skaliter

Hagar Kalinski

Igor Mett

Original Assignee

Quark Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-20

Filing date

2009-03-17

Publication date

2015-08-11

2009-03-17 Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc

2015-08-11 Publication of BRPI0909270A2 publication Critical patent/BRPI0909270A2/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0909270-6A 2008-03-20 2009-03-17 Sirna Compounds for Inhibition of rtp801 BRPI0909270A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7018108P	2008-03-20	2008-03-20
PCT/IL2009/000302 WO2009116037A2 (en)	2008-03-20	2009-03-17	NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801

Publications (1)

Publication Number	Publication Date
BRPI0909270A2 true BRPI0909270A2 (en)	2015-08-11

Family

ID=41091311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909270-6A BRPI0909270A2 (en)	2008-03-20	2009-03-17	Sirna Compounds for Inhibition of rtp801

Country Status (11)

Country	Link
US (1)	US20110028531A1 (en)
EP (1)	EP2268316A4 (en)
JP (1)	JP2011517404A (en)
KR (1)	KR20100132531A (en)
CN (1)	CN102026670A (en)
AU (1)	AU2009227549A1 (en)
BR (1)	BRPI0909270A2 (en)
CA (1)	CA2718765A1 (en)
MX (1)	MX2010010303A (en)
RU (1)	RU2010138558A (en)
WO (1)	WO2009116037A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101094617B1 (en)	2004-08-16	2011-12-15	사일런스 테라퓨틱스 아게	Therapeutic Uses of Altipi801 Inhibitors
JP2010518880A (en)	2007-02-26	2010-06-03	クアーク・ファーマスーティカルス、インコーポレイテッド	Inhibitors of RTP801 and their use in the treatment of diseases
US8637482B2 (en) *	2009-06-08	2014-01-28	Quark Pharmaceuticals, Inc.	Methods for treating chronic kidney disease
EP3587580A1 (en)	2010-10-27	2020-01-01	Devgen NV	Down-regulating gene expression in insect pests
AU2011338682B2 (en) *	2010-12-06	2017-04-27	Quark Pharmaceuticals, Inc.	Double stranded oligonucleotide compounds comprising threose modifications
BR112014010769B1 (en)	2011-11-03	2021-08-03	Quark Pharmaceuticals, Inc	USE OF A DOUBLE TAPE RNA COMPOUND TO PREPARE A DRUG TO TREAT MEN'S DISEASE
WO2013070821A1 (en)	2011-11-08	2013-05-16	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the nervous system
DK2895607T3 (en)	2012-09-12	2021-05-25	Quark Pharmaceuticals Inc	DOUBLE-STRING OLIGONUCLEOTIDE MOLECULES FOR DDIT4 AND METHODS FOR USING IT
TW201620526A (en)	2014-06-17	2016-06-16	愛羅海德研究公司	Composition and method for inhibiting α-1 antitrypsin gene expression
AU2017368050A1 (en)	2016-11-29	2019-06-20	Puretech Lyt, Inc.	Exosomes for delivery of therapeutic agents
TW202436621A (en)	2017-01-10	2024-09-16	美商愛羅海德製藥公司	Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6235886B1 (en) *	1993-09-03	2001-05-22	Isis Pharmaceuticals, Inc.	Methods of synthesis and use
DE69431669T2 (en) *	1993-09-02	2003-10-23	Ribozyme Pharmaceuticals, Inc.	ENZYMATIC NUCLEIC ACID THAT CONTAINS NON-NUCLEOTIDS
US5998203A (en) *	1996-04-16	1999-12-07	Ribozyme Pharmaceuticals, Inc.	Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US5753789A (en) *	1996-07-26	1998-05-19	Yale University	Oligonucleotides containing L-nucleosides
JP3756313B2 (en) *	1997-03-07	2006-03-15	武今西	Novel bicyclonucleosides and oligonucleotide analogues
US6251666B1 (en) *	1997-03-31	2001-06-26	Ribozyme Pharmaceuticals, Inc.	Nucleic acid catalysts comprising L-nucleotide analogs
US6091048A (en) *	1997-05-16	2000-07-18	Illinois Tool Works Inc.	Welding machine with automatic parameter setting
US6506559B1 (en) *	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
RU2233844C2 (en) *	1999-02-12	2004-08-10	Санкио Компани Лимитед	New nucleoside and oligonucleotide analogues
WO2001029058A1 (en) *	1999-10-15	2001-04-26	University Of Massachusetts	Rna interference pathway genes as tools for targeted genetic interference
GB9925459D0 (en) *	1999-10-27	1999-12-29	Plant Bioscience Ltd	Gene silencing
GB9927444D0 (en) *	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
US20050020525A1 (en) *	2002-02-20	2005-01-27	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202979B2 (en) *	2002-02-20	2012-06-19	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
KR20080023768A (en) *	2000-03-30	2008-03-14	화이트헤드 인스티튜트 포 바이오메디칼 리서치	RNA sequence specific mediator of RNA interference
US6693187B1 (en) *	2000-10-17	2004-02-17	Lievre Cornu Llc	Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
KR100909681B1 (en) *	2000-12-01	2009-07-29	막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우.	Small RNA molecules that mediate JR interference
US20070032441A1 (en) *	2001-05-18	2007-02-08	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20060217331A1 (en) *	2001-05-18	2006-09-28	Sirna Therapeutics, Inc.	Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US7629456B2 (en) *	2001-10-26	2009-12-08	Noxxon Pharma Ag	Modified L-nucleic acid
US7452987B2 (en) *	2002-08-05	2008-11-18	Silence Therapeutics Aktiengesellschaft (Ag)	Interfering RNA molecules
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2213738B1 (en) *	2002-11-14	2012-10-10	Dharmacon, Inc.	siRNA molecules targeting Bcl-2
CA2522637C (en) *	2003-04-17	2014-01-21	Alnylam Pharmaceuticals, Inc.	Modified irna agents
AU2004248136B2 (en) *	2003-06-02	2011-09-15	University Of Massachusetts	Methods and compositions for controlling efficacy of RNA silencing
ATE485394T1 (en) *	2003-06-02	2010-11-15	Univ Massachusetts	METHODS AND COMPOSITIONS FOR IMPROVING THE EFFECTIVENESS AND SPECIFICITY OF FNAI
KR101147147B1 (en) *	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Modified polynucleotides for reducing off-target effects in rna interference
CA2569419A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
WO2006020768A2 (en) *	2004-08-10	2006-02-23	Alnylam Pharmaceuticals, Inc.	Chemically modified oligonucleotides
KR101094617B1 (en) *	2004-08-16	2011-12-15	사일런스 테라퓨틱스 아게	Therapeutic Uses of Altipi801 Inhibitors
DOP2007000015A (en) *	2006-01-20	2007-08-31	Quark Biotech Inc	THERAPEUTIC USES OF RTP801 INHIBITORS
CN103614375A (en) *	2006-05-11	2014-03-05	阿尔尼拉姆医药品有限公司	Composition and method for inhibiting expression of PCSK9 gene
JP2010507387A (en) *	2006-10-25	2010-03-11	クアーク・ファーマスーティカルス、インコーポレイテッド	Novel siRNA and method of using the same
JP2010518880A (en) *	2007-02-26	2010-06-03	クアーク・ファーマスーティカルス、インコーポレイテッド	Inhibitors of RTP801 and their use in the treatment of diseases
US20100292301A1 (en) *	2007-02-28	2010-11-18	Elena Feinstein	Novel sirna structures
US8614309B2 (en) *	2007-10-03	2013-12-24	Quark Pharmaceuticals, Inc.	Double-stranded RNA directed to CASP2 and methods of use thereof

2009
- 2009-03-17 JP JP2011500346A patent/JP2011517404A/en active Pending
- 2009-03-17 KR KR1020107023465A patent/KR20100132531A/en not_active Ceased
- 2009-03-17 CA CA2718765A patent/CA2718765A1/en not_active Abandoned
- 2009-03-17 AU AU2009227549A patent/AU2009227549A1/en not_active Abandoned
- 2009-03-17 CN CN2009801169940A patent/CN102026670A/en active Pending
- 2009-03-17 MX MX2010010303A patent/MX2010010303A/en unknown
- 2009-03-17 RU RU2010138558/10A patent/RU2010138558A/en not_active Application Discontinuation
- 2009-03-17 EP EP09722841A patent/EP2268316A4/en not_active Withdrawn
- 2009-03-17 US US12/736,230 patent/US20110028531A1/en not_active Abandoned
- 2009-03-17 BR BRPI0909270-6A patent/BRPI0909270A2/en not_active IP Right Cessation
- 2009-03-17 WO PCT/IL2009/000302 patent/WO2009116037A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2009116037A3 (en)	2010-03-11
JP2011517404A (en)	2011-06-09
CN102026670A (en)	2011-04-20
MX2010010303A (en)	2010-10-20
US20110028531A1 (en)	2011-02-03
KR20100132531A (en)	2010-12-17
AU2009227549A1 (en)	2009-09-24
RU2010138558A (en)	2012-03-27
EP2268316A4 (en)	2011-05-25
CA2718765A1 (en)	2009-09-24
WO2009116037A2 (en)	2009-09-24
EP2268316A2 (en)	2011-01-05

Publication	Publication Date	Title
BRPI0909270A2 (en)	2015-08-11	Sirna Compounds for Inhibition of rtp801
EP2299999A4 (en)	2012-01-25	INHIBITORS OF STAT3
LTPA2019009I1 (en)	2019-04-10	Tetracycline compounds have been substituted for C7-fluorine
SMT201600267B (en)	2016-08-31	INHIBITORS OF SYK IMIDAZOPIRAZINICI
DK2346888T3 (en)	2013-03-25	Process for the preparation of compounds useful as SGLT inhibitors
EP2350110A4 (en)	2013-04-03	NEW GLYCOSIDE OF STÉVIOL
SMT201600008B (en)	2016-02-25	PIRIDAZINONE COMPOUNDS
DK3289876T3 (en)	2022-10-10	COMPOUNDS FOR THE TREATMENT OF CANCER
BRPI0923433A2 (en)	2015-08-11	Synthesis of Fucosylated Compounds
DOP2012000114A (en)	2012-08-15	BROMODOMINIUM INHIBITOR OF BENZODIAZEPINA
BRPI0922880A2 (en)	2018-07-24	kinase inhibitor compounds
DK3354650T3 (en)	2022-05-30	Compounds useful as inhibitors of ATR kinase
DK2414362T3 (en)	2014-09-22	PYRIMIDINE-SUBSTITUTED PURINE COMPOUNDS AS KINASE INHIBITORS
BRPI1013614A2 (en)	2019-09-24	substituted spiro-amide compounds
BR112013014943A2 (en)	2016-09-13	compounds useful for the treatment of AIDS
EP2272817A4 (en)	2011-12-14	INHIBITOR OF PAI-1
BRPI1015274A2 (en)	2016-05-03	installation for surface treatment of parts
BRPI0920621A2 (en)	2017-10-17	processes for macrolide compound synthesis
IL208136A0 (en)	2010-12-30	Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
BRPI0912475A2 (en)	2018-01-09	compounds as kinase inhibitors
BRPI0820677A2 (en)	2014-10-07	MIXTURES OF PESTICIDATED COMPOUNDS
UY33156A (en)	2011-07-29	NEW TIENOPIRROL COMPOUNDS
SMT201600031B (en)	2016-02-25	HETEROCYCLIC COMPOUNDS OF PHENOSSIMETHYL
BRPI0813788A2 (en)	2014-12-30	PROCESS FOR PREPARATION OF ALILA METACRILATE
CU23884B1 (en)	2013-04-19	DERIVATIVES OF DIBENZOTIAZEPINA

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.